By Kristen Osenga Cross-posted with permission from Professor Osenga’s December 8, 2025, LinkedIn article I’ve seen a lot of misinformation circulating online lately about patents and their role in drug […]
TPLFA: Protecting Predatory Infringers
By Michael Doane The CEO of a small technology-based company with many groundbreaking patents in its field once asked me what the point was of obtaining patents when the company […]
IPPI Cautions that Pharmaceutical Tariffs Would Harm Patients and U.S. Innovation Leadership
IPPI has submitted formal comments to the U.S. Department of Commerce regarding its Section 232 investigation of pharmaceutical imports, cautioning against imposing tariffs on medicines and their ingredients. In our […]
RESTORE, PERA and PREVAIL: Bills that fix problems with the patent system
By Kristen Jakobsen Osenga As the 118th Congress drew to a close at the end of 2024, there was a spate of intellectual property activity on Capitol Hill. I was […]
[Archived Post] From Great Ideas to Global Impact – A Talk with Andrew Byrnes
The following post comes from Tuan Tran, a rising 3L at Scalia Law and a Research Assistant at C-IP2. Click on image for full-size PDF flyer. Small ideas can lead […]
[Archived Post] Comment of 25 Law Professors, Economists, and Former U.S. Government Officials in Response to EU Commission Call for Evidence on Standard-Essential Patents
Led by Prof. Adam Mossoff and C-IP2 Senior Fellow and Senior Scholar Prof. Jonathan M. Barnett, twenty-five law professors, economists, and former United States Government officials—including C-IP2 Advisory Board members the […]
[Archived Post] Reply and Response to C-IP2’s March 4, 2021, Blogpost on UC Hastings’ Evergreen Drug Patent Search Database
C-IP2’s original post on the UC Hastings’ Evergreen Drug Patent Search Database can be read here. Reply to Blog Post on UC Hastings’ Evergreen Drug Patent Search Database Robin Feldman […]
[Archived Post] Panel Discussion: Vaccines, Intellectual Property, and Global Equity
The following post comes from Colin Kreutzer, a 2E at Scalia Law and a Research Assistant at C-IP2. The COVID-19 pandemic has shined a spotlight on the role of intellectual […]
[Archived Post] A View from Both Sides: COVID-19, the TRIPS Waiver, IP Rights, and How to Increase the Supply of Vaccines
Issue The United States and other wealthy nations have access to plenty of COVID-19 vaccine doses and thus are beginning to get the pandemic under control, while less affluent countries […]
[Archived Post] WTO IP Waiver Too Simplistic: Global Vaccine Tech-Transfer Needs Other Strategies
By Yogesh Pai Since October 2020, India and South Africa, joined by two-thirds of the WTO Members (African Group, LDCs and most of developing world) have been actively pursuing other […]